Cover Image
市場調查報告書

威爾姆氏腫瘤蛋白:開發中產品分析

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018

出版商 Global Markets Direct 商品編碼 516032
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
威爾姆氏腫瘤蛋白:開發中產品分析 Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2018
出版日期: 2018年11月20日 內容資訊: 英文 68 Pages
簡介

本報告提供以威爾姆氏腫瘤蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

威爾姆氏腫瘤蛋白;概要

威爾姆氏腫瘤蛋白;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc
  • 大塚集團
  • 大日本住友製藥
  • Vaximm AG

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1794TDB

Summary:

According to the recently published report 'Wilms Tumor Protein - Pipeline Review, H2 2018'; Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO.

The report 'Wilms Tumor Protein - Pipeline Review, H2 2018' outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Leukemias, Pancreatic Cancer, Soft Tissue Sarcoma, Solid Tumor, Adrenal Gland Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
  • The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wilms Tumor Protein (WT33 or WT1) - Overview
    • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
    • Inovio Pharmaceuticals Inc
    • Otsuka Holdings Co Ltd
    • Scancell Holdings Plc
    • SELLAS Life Sciences Group Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Vaximm AG
  • Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
    • galinpepimut-S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-5401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCV-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ombipepimut-s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target WT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VXM-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Wilms Tumor Protein (WT33 or WT1) - Dormant Products
  • Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
  • Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
      • Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
      • Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
      • Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
      • Jun 04, 2018: SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018
      • Jun 01, 2018: Boston Biomedical Highlights Presentations on Investigational Agent DSP-7888 (ombipepimut-S) at ASCO 2018
      • May 17, 2018: SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
      • May 17, 2018: Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018
      • May 09, 2018: SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)
      • Apr 25, 2018: Boston Biomedical Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S)
      • Mar 19, 2018: SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
      • Feb 27, 2018: Data From SELLAS Life Sciences' Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology's Journal, Blood Advances
      • Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting
      • Nov 27, 2017: Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
      • Nov 01, 2017: Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indications, H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Companies, H2 2018 (Contd..2), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2018
  • Pipeline by Otsuka Holdings Co Ltd, H2 2018
  • Pipeline by Scancell Holdings Plc, H2 2018
  • Pipeline by SELLAS Life Sciences Group Inc, H2 2018
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
  • Pipeline by Vaximm AG, H2 2018
  • Dormant Projects, H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
Back to Top